Improving brain penetration of radiolabeled TKI PET tracers through blood brain barrier transporter inhibitio
Completed
- Conditions
- CancerBrain metastasesTyrosinse Kinase InhibitorsDrug Transporters
- Registration Number
- NL-OMON25665
- Lead Sponsor
- etherlands Cancer Institute - Antoni van Leeuwenhoek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 8
Inclusion Criteria
The study population consists of cancer patients with advanced or metastatic solid tumors for whom no standard
therapy is available or for whom a TKI which is a PgP/BCRP substrate is a standard therapeutic option (erlotinib,
sunitinib, imatinib, gefitinib, sorafenib, lapatinib, crizotinib, vemurafenib).
Exclusion Criteria
- Known brain metastases;
- Patients who have had previous treatment with central nervous system irradiation;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improved CNS penetration of 11C erlotinib after PGP/BCRP inhibitor administration.
- Secondary Outcome Measures
Name Time Method